CHAPEL HILL, N.C., March 08, 2016 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced that Prabhavathi Fernandes, Ph.D., president and chief executive officer of Cempra, will participate in a Nature webcast, featuring five innovative antibiotic companies. The webcast, part of the BioPharma Dealmakers series, is scheduled to begin at 11:00 a.m. ET/8:00 a.m. PT on March 9, 2016.
The webcast will feature experts from several companies in the field examining what is being done to combat antibiotic resistance, with discussion moderated by Raveena Bhambra, editor of BioPharma Dealmakers. Participants will be:
- Dr. Prabhavathi Fernandes Ph.D., Founder, President and CEO of Cempra Inc.
- Professor Anthony R.M. Coates, Chief Scientific Officer of Helperby Therapeutics
- Dr. David Huang, Chief Medical Officer of Motif Bio
- Dr. Glenn Dale, Head of Early Development, Antimicrobials of Polyphor
- Dr. Marc Lemonnier, Co-founder and CEO of Antabio
The webcast will also include a roundtable discussion and a Q&A section. Interested parties may register here to listen to the event.
About Cempra, Inc.
Cempra, Inc. is a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases. Cempra's two lead product candidates are currently in advanced clinical development. Solithromycin (CEM-101) has successfully completed two Phase 3 clinical trials for community-acquired bacterial pneumonia (CABP) and is licensed to strategic commercial partner Toyama Chemical Co., Ltd., a subsidiary of FUJIFILM Holdings Corporation, for certain exclusive rights in Japan. Solithromycin is also in a Phase 3 clinical trial for uncomplicated urogenital urethritis caused by Neisseria gonorrhoeae or chlamydia. Cempra is contracted with BARDA for the development of solithromycin for pediatric use. Three formulations, intravenous, oral capsules and a suspension formulation are in a Phase 1b trial in children from birth to 17 years of age. Taksta™ is Cempra's second product candidate, which is being developed for acute bacterial skin and skin structure Infections (ABSSSI) and is also expected to be tested in an exploratory study for chronic oral treatment of refractory infections in bones and joints. Both products seek to address the need for new treatments targeting drug-resistant bacterial infections in the hospital and in the community. Cempra has also synthesized novel macrolides for non-antibiotic uses such as the treatment of chronic inflammatory diseases, endocrine diseases and gastric motility disorders. Cempra was founded in 2006 and is headquartered in Chapel Hill, N.C. For additional information about Cempra please visit www.cempra.com.